181 related articles for article (PubMed ID: 37615836)
1. Validation of the Peak Pruritus Numerical Rating Scale as a Patient-Reported Outcome Measure in Prurigo Nodularis.
Kwatra SG; Rodriguez D; Dias-Barbosa C; Budhiarso I; Fofana F; Vernon M; Gabriel S; Piketty C; Puelles J
Dermatol Ther (Heidelb); 2023 Oct; 13(10):2403-2416. PubMed ID: 37615836
[TBL] [Abstract][Full Text] [Related]
2. The Sleep Disturbance Numerical Rating Scale: Content Validity, Psychometric Validation, and Meaningful Within-Patient Change in Prurigo Nodularis.
Ständer S; Fofana F; Dias-Barbosa C; Rodriguez D; Budhiarso I; Jabbar-Lopez ZK; Piketty C; Vernon M; Puelles J
Dermatol Ther (Heidelb); 2023 Jul; 13(7):1587-1602. PubMed ID: 37329468
[TBL] [Abstract][Full Text] [Related]
3. Validation of Psychometric Properties of the Itch Numeric Rating Scale for Pruritus Associated With Prurigo Nodularis: A Secondary Analysis of a Randomized Clinical Trial.
Kimel M; Zeidler C; Kwon P; Revicki D; Ständer S
JAMA Dermatol; 2020 Dec; 156(12):1354-1358. PubMed ID: 32936233
[TBL] [Abstract][Full Text] [Related]
4. Psychometric validation and meaningful change thresholds of the Worst Itching Intensity Numerical Rating Scale for assessing itch in patients with chronic kidney disease-associated pruritus.
Vernon MK; Swett LL; Speck RM; Munera C; Spencer RH; Wen W; Menzaghi F
J Patient Rep Outcomes; 2021 Dec; 5(1):134. PubMed ID: 34952964
[TBL] [Abstract][Full Text] [Related]
5. Worst itch numerical rating scale for prurigo nodularis: a psychometric evaluation.
Ständer S; Zeidler C; Pereira M; Szepietowski JC; McLeod L; Qin S; Williams N; Sciascia T; Augustin M
J Eur Acad Dermatol Venereol; 2022 Apr; 36(4):573-581. PubMed ID: 34908192
[TBL] [Abstract][Full Text] [Related]
6. Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances.
Ständer S; Yosipovitch G; Lacour JP; Legat FJ; Paul C; Reich A; Chaouche K; Ahmad F; Piketty C
J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):1820-1825. PubMed ID: 35766128
[TBL] [Abstract][Full Text] [Related]
7. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.
Ständer S; Yosipovitch G; Legat FJ; Lacour JP; Paul C; Narbutt J; Bieber T; Misery L; Wollenberg A; Reich A; Ahmad F; Piketty C
N Engl J Med; 2020 Feb; 382(8):706-716. PubMed ID: 32074418
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study.
Sofen H; Bissonnette R; Yosipovitch G; Silverberg JI; Tyring S; Loo WJ; Zook M; Lee M; Zou L; Jiang GL; Paolini JF
EClinicalMedicine; 2023 Mar; 57():101826. PubMed ID: 36816342
[TBL] [Abstract][Full Text] [Related]
9. Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
Kwatra SG; Yosipovitch G; Legat FJ; Reich A; Paul C; Simon D; Naldi L; Lynde C; De Bruin-Weller MS; Nahm WK; Sauder M; Gharib R; Barbarot S; Szepietowski JC; Conrad C; Fleischer A; Laquer VT; Misery L; Serra-Baldrich E; Lapeere H; Ahmad F; Jabbar Lopez ZK; Piketty C; Ständer S;
N Engl J Med; 2023 Oct; 389(17):1579-1589. PubMed ID: 37888917
[TBL] [Abstract][Full Text] [Related]
10. Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response.
Husein-ElAhmed H; Steinhoff M
J Dermatolog Treat; 2022 May; 33(3):1547-1553. PubMed ID: 33200955
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: Results from a randomised, double-blind, placebo-controlled, phase II/III clinical study in patients aged ≥13 years.
Yokozeki H; Murota H; Matsumura T; Komazaki H;
Br J Dermatol; 2024 Apr; ():. PubMed ID: 38629497
[TBL] [Abstract][Full Text] [Related]
12. A systematic review of interleukin-31 inhibitors in the treatment of prurigo nodularis.
Nilforoushzadeh MA; Heidari N; Ghane Y; Heidari A; Hajikarim-Hamedani A; Hosseini S; Jaffary F; Najar Nobari M; Tavakolzadeh P; Najar Nobari N
Inflammopharmacology; 2024 Apr; 32(2):991-1003. PubMed ID: 38332383
[TBL] [Abstract][Full Text] [Related]
13. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis.
Yosipovitch G; Reaney M; Mastey V; Eckert L; Abbé A; Nelson L; Clark M; Williams N; Chen Z; Ardeleanu M; Akinlade B; Graham NMH; Pirozzi G; Staudinger H; Plaum S; Radin A; Gadkari A
Br J Dermatol; 2019 Oct; 181(4):761-769. PubMed ID: 30729499
[TBL] [Abstract][Full Text] [Related]
14. Assessing Itch Severity: Content Validity and Psychometric Properties of a Patient-Reported Pruritus Numeric Rating Scale in Atopic Dermatitis.
Rams A; Baldasaro J; Bunod L; Delbecque L; Strzok S; Meunier J; ElMaraghy H; Sun L; Pierce E
Adv Ther; 2024 Apr; 41(4):1512-1525. PubMed ID: 38363461
[TBL] [Abstract][Full Text] [Related]
15. Estimating meaningful change thresholds for Skin Pain-Numeric Rating Scale, Sleep-Numeric Rating Scale and Dermatology Life Quality Index in patients with prurigo nodularis.
Stander S; Kim BS; Guillemin I; Rhoten S; Wratten S; Brookes E; O'Malley JT; Bansal A; Msihid J; Thomas R; Bahloul D
J Eur Acad Dermatol Venereol; 2024 Feb; ():. PubMed ID: 38329222
[TBL] [Abstract][Full Text] [Related]
16. Modulation of Neuroimmune and Epithelial Dysregulation in Patients With Moderate to Severe Prurigo Nodularis Treated With Nemolizumab.
Deng J; Liao V; Parthasarathy V; Cornman HL; Kambala A; Kwatra MM; Ständer S; Piketty C; Chaskar P; Krishnaswamy JK; Julia V; Kwatra SG
JAMA Dermatol; 2023 Sep; 159(9):977-985. PubMed ID: 37556125
[TBL] [Abstract][Full Text] [Related]
17. Responder analysis using clinically meaningful thresholds: Post hoc analyses from randomized dupilumab clinical trials in patients with prurigo nodularis.
Kwatra SG; Yosipovitch G; Ständer S; Guillemin I; Msihid J; Bansal A; Makhija M; Wiggins S; Zahn J; Thomas RB; Bahloul D
J Eur Acad Dermatol Venereol; 2024 May; ():. PubMed ID: 38785405
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of dupilumab in prurigo nodularis in elderly patient.
Giura MT; Viola R; Fierro MT; Ribero S; Ortoncelli M
Dermatol Ther; 2020 Jan; 33(1):e13201. PubMed ID: 31856368
[TBL] [Abstract][Full Text] [Related]
19. The effectiveness and safety of dupilumab in the management of refractory prurigo nodularis in 45 Chinese patients: A real-life observational study.
Fang HY; Lian CH
J Dermatol; 2023 Aug; 50(8):1084-1087. PubMed ID: 37088954
[TBL] [Abstract][Full Text] [Related]
20. A population pharmacokinetic-pharmacodynamic model evaluating efficacy of nalbuphine extended-release in patients with prurigo nodularis.
Eudy-Byrne R; Riggs M; Hawi A; Sciascia T; Rohatagi S
Br J Clin Pharmacol; 2023 Jul; 89(7):2088-2101. PubMed ID: 36680419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
